Literature DB >> 16384937

HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis.

Willem Maat1, Geert W Haasnoot, Frans H J Claas, Nicoline E Schalij-Delfos, Geziena M T Schreuder, Martine J Jager.   

Abstract

PURPOSE: To assess whether human leukocyte antigen class I and class II alleles confer susceptibility to uveal melanoma or are related to specific clinical or tumor characteristics and survival.
METHODS: Between 1990 and 2004, 235 consecutive Dutch patients with diagnoses of primary uveal melanoma were typed for HLA class I and II, either by complement-dependent cytotoxicity test or by DNA-based technique. Allele frequencies were compared with those of a control group that consisted of 2440 healthy Dutch blood donors. In addition, allele frequencies of 138 patients with uveal melanoma, who underwent enucleation as primary treatment, were compared for tumor characteristics and survival.
RESULTS: With regard to tumor characteristics, correlations between HLA-DR13 and tumor size, HLA-B35 and spindle cell type, and HLA-B60 and ciliary body involvement were observed before correction for the number of alleles tested. Correlation was found between the presence of HLA-B44 and decreased survival. We did not find any allele that correlated with susceptibility to uveal melanoma after correction for the number of comparisons between patients and controls.
CONCLUSIONS: This study shows that HLA class I and II antigens do not contribute to an increased genetic susceptibility to uveal melanoma. This does not exclude an important role for HLA antigens in immune surveillance against uveal melanoma and their metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16384937     DOI: 10.1167/iovs.05-1122

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Authors:  Gülçin Gezgin; Sietse J Luk; Jinfeng Cao; Mehmet Dogrusöz; Dirk M van der Steen; Renate S Hagedoorn; Daniëlle Krijgsman; Pieter A van der Velden; Matthew G Field; Gregorius P M Luyten; Karoly Szuhai; J William Harbour; Ekaterina S Jordanova; Mirjam H M Heemskerk; Martine J Jager
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

Review 2.  Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

Authors:  Martine J Jager; J Antonio Bermudez Magner; Bruce R Ksander; Sander R Dubovy
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

Review 3.  Genetics of primary intraocular tumors.

Authors:  Nisha Nagarkatti-Gude; Yujuan Wang; Mohammad Javed Ali; Santosh G Honavar; Martine J Jager; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-08       Impact factor: 3.070

Review 4.  [Human leukocyte antigen (HLA) system in ophthalmology].

Authors:  T Lapp; D Reinhold; D Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

Review 5.  Blood biomarkers for uveal melanoma.

Authors:  Pierre L Triozzi; Arun D Singh
Journal:  Future Oncol       Date:  2012-02       Impact factor: 3.674

Review 6.  The biology of uveal melanoma.

Authors:  Adriana Amaro; Rosaria Gangemi; Francesca Piaggio; Giovanna Angelini; Gaia Barisione; Silvano Ferrini; Ulrich Pfeffer
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

Review 7.  HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Authors:  Zahra Souri; Annemijn P A Wierenga; Arend Mulder; Aart G Jochemsen; Martine J Jager
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

8.  Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.

Authors:  Veronica Aedo-Lopez; Camille L Gérard; Sarah Boughdad; Bianca Gautron Moura; Gregoire Berthod; Antonia Digklia; Krisztian Homicsko; Niklaus Schaefer; Rafael Duran; Michel A Cuendet; Olivier Michielin
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.